NXGL: NEXGEL Inc Projected Price to Earnings

NEXGEL, Inc. (NXGL) relies on the production of specialized hydrogel dressings, which generate stable demand across clinics. The executive team is actively expanding the product range and optimizing production output. A flawless image and physician confidence in the brand's safety validate the quality of the products. This forward P/E chart visualizes the ratio of the share price to expected earnings, and 0.00 reflects the latest value of the metric.

NXGL - NEXGEL Market Cap to Projected Earnings over the range 07/04/2022 - 11/13/2026

Analytical breakdowns and data insights for company NEXGEL Inc (NXGL)

- stock value and consensus price forecast:

Price Chart NEXGEL|NXGL - Price Target Chart

- market capitalization information:

Market Valuation NEXGEL Inc.|NXGL - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share NEXGEL|NXGL - Book Valuation of Business|Market Value to Book Value Ratio nexgel.com|NXGL - Total Business Assets

- debt burden and liquidity indicators:

- earnings and market ratios statistics:

NXGL - Net Income|Projected Future Earnings NEXGEL, Inc.|NXGL - Market Cap to Earnings|Future Price to Earnings NEXGEL, Inc|NXGL - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio NEXGEL Inc.|NXGL - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months NEXGEL|NXGL - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months nexgel.com|NXGL - Earnings per share growth this year|Earnings growth forecast for next year NEXGEL, Inc.

Summary company analysis:NXGL NEXGEL

This indicator reflects the market value of the share relative to expected earnings per share, allowing for an assessment of the premium paid for the business's future income. Analyzing the forward P/E ratio of NEXGEL, Inc. (NXGL) helps determine the fairness of its valuation, given that electron-beam crosslinking patents and FDA approval create high marginal stability protected from generic competition.

Direct competitors